{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:01:46Z","timestamp":1791864106787,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115475","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T02:29:14Z","timestamp":1745634554000},"page":"115475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5719-0738","authenticated-orcid":false,"given":"Nan","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0820","authenticated-orcid":false,"given":"Karlijn E.P.E.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-3538","authenticated-orcid":false,"given":"Thiemo J.A.","family":"van Nijnatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne M.E.","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Tol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-8665","authenticated-orcid":false,"given":"Loes","family":"Kooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4472-4257","authenticated-orcid":false,"given":"Marie-Jeanne T.F.D.","family":"Vrancken-Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-824X","authenticated-orcid":false,"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri C.","family":"Voogd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3935-7440","authenticated-orcid":false,"given":"Vivianne C.G.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.E.","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2025.115475_bib1","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ejca.2025.115475_bib2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/bjc.2013.6","article-title":"Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study","volume":"108","author":"Walters","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.115475_bib3","unstructured":"Integraal Kankercentrum Nederland. Borstkanker in Nederland. https:\/\/iknl.nl\/borstkankercijfers. Accessed 2024."},{"issue":"5","key":"10.1016\/j.ejca.2025.115475_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/cge.13900","article-title":"Molecular intrinsic versus clinical subtyping in breast cancer: a comprehensive review","volume":"99","author":"Szymiczek","year":"2021","journal-title":"Clin Genet"},{"issue":"13","key":"10.1016\/j.ejca.2025.115475_bib5","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-22-0283","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","volume":"29","author":"Raghav","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.115475_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-017-4529-5","article-title":"Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010","volume":"167","author":"Malmgren","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ejca.2025.115475_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-016-4066-7","article-title":"Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis","volume":"161","author":"Leone","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"4785","key":"10.1016\/j.ejca.2025.115475_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"4905","key":"10.1016\/j.ejca.2025.115475_bib9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejca.2025.115475_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20\u2009446 metastatic breast cancer patients in the 2008-2017 ESME cohort","volume":"6","author":"Grinda","year":"2021","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.ejca.2025.115475_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2025.115475_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115475_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115475_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115475_bib15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.115475_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pupt.2014.01.005","article-title":"Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view","volume":"27","author":"Saturni","year":"2014","journal-title":"Pulm Pharm Ther"},{"issue":"2","key":"10.1016\/j.ejca.2025.115475_bib17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10549-021-06178-8","article-title":"Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry","volume":"188","author":"Ibragimova","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ejca.2025.115475_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10549-023-07235-0","article-title":"Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry","volume":"205","author":"Geurts","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ejca.2025.115475_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.ejca.2025.115475_bib20","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115475_bib21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115475_bib22","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2025.115475_bib23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jnci\/92.7.550","article-title":"GM. Tumor characteristics and clinical outcome of elderly women with breast cancer","volume":"92","author":"Elledge","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.ejca.2025.115475_bib24","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3390\/cancers11091239","article-title":"Trends in overall survival and treatment patterns in two large population-based cohorts of patients with breast and colorectal cancer","volume":"11","author":"Abbema","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejca.2025.115475_bib25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-022-06832-9","article-title":"Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry","volume":"198","author":"Ibragimova","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.ejca.2025.115475_bib26","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(07)70378-9","article-title":"Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology","volume":"8","author":"Wildiers","year":"2007","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115475_bib27","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10549-012-2116-3","article-title":"The influence of non-clinical patient factors on medical oncologists' decisions to recommend breast cancer adjuvant chemotherapy","volume":"134","author":"Pini","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2025.115475_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.breast.2020.04.009","article-title":"Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort","volume":"52","author":"Frank","year":"2020","journal-title":"Breast"},{"issue":"12","key":"10.1016\/j.ejca.2025.115475_bib29","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115475_bib30","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdi816","article-title":"ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC)","volume":"16","author":"Kataja","year":"2005","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115475_bib31","doi-asserted-by":"crossref","first-page":"v15","DOI":"10.1093\/annonc\/mdq160","article-title":"ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Cardoso","year":"2010","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115475_bib32","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.21.02006","article-title":"Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108)","volume":"40","author":"Khan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2025.115475_bib33","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115475_bib34","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/SLA.0000000000004767","article-title":"Early locoregional breast surgery and survival in de novo metastatic breast cancer in the multicenter national ESME cohort","volume":"277","author":"Hotton","year":"2023","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejca.2025.115475_bib35","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115475_bib36","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1053\/j.semnuclmed.2022.03.004","article-title":"A role of FDG-PET\/CT for response evaluation in metastatic breast cancer?","volume":"52","author":"Hildebrandt","year":"2022","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.ejca.2025.115475_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.20892\/j.issn.2095-3941.2017.0044","article-title":"Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer","volume":"14","author":"Chen","year":"2017","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ejca.2025.115475_bib38","unstructured":"Netherlands Comprehensive Cancer Organisation (IKNL). (2024). Borstkankercijfers. Retrieved March 27, 2025, from https:\/\/iknl.nl\/borstkankercijfers."},{"issue":"3","key":"10.1016\/j.ejca.2025.115475_bib39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-014-2916-8","article-title":"Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer","volume":"145","author":"Yardley","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.ejca.2025.115475_bib40","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2025.115475_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102924","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial","volume":"9","author":"Hurvitz","year":"2024","journal-title":"ESMO Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:35:18Z","timestamp":1762342518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"alternative-id":["S0959804925002564"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115475","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115475"}}